Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 12.32% is 56% below its 5-year average of 27.72%, near the low end of its 5-year range (12.32%–41.98%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.68% below its 12-month average of 15.53%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 12.32%.
RETURN ON EQUITY (ROE)
12.32%
RETURN ON EQUITY (ROE) AVG TTM
15.53%
RETURN ON EQUITY (ROE) AVG 3Y
20.19%
RETURN ON EQUITY (ROE) AVG 5Y
27.72%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-20.68%
CURRENT VS 3Y AVG
-38.98%
CURRENT VS 5Y AVG
-55.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 533 covered companies
CURRENT VS SECTOR MEDIAN
+130.65%
vs the sector median at left
InMode Ltd.
Market Cap
$805.85M
Return on Equity (ROE)
12.32%
TTM Avg
15.53%
3Y Avg
20.19%
5Y Avg
27.72%
Market Cap
$804.28M
Return on Equity (ROE)
-37.38%
TTM Avg
-29.74%
3Y Avg
-41.86%
5Y Avg
-72.28%
Market Cap
$819.78M
Return on Equity (ROE)
-34.83%
TTM Avg
-64.71%
3Y Avg
-59.77%
5Y Avg
-96.53%
Market Cap
$789.11M
Return on Equity (ROE)
-16.56%
TTM Avg
0.55%
3Y Avg
-10.56%
5Y Avg
-13.37%
Market Cap
$825.76M
Return on Equity (ROE)
-97.08%
TTM Avg
-96.94%
3Y Avg
-22.72%
5Y Avg
-22.72%
Market Cap
$784.88M
Return on Equity (ROE)
-13.30%
TTM Avg
11.91%
3Y Avg
154.09%
5Y Avg
54.89%
Market Cap
$834.78M
Return on Equity (ROE)
-28.46%
TTM Avg
-48.75%
3Y Avg
-33.66%
5Y Avg
-33.66%
Market Cap
$841.42M
Return on Equity (ROE)
-33.06%
TTM Avg
-24.59%
3Y Avg
-41.17%
5Y Avg
-18.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMode Ltd. (INMD) | $805.85M | 12.32% | 15.53% | 20.19% | 27.72% |
| Apnimed, Inc. (APMD)vs › | $807.22M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $804.28M | -37.38% | -29.74% | -41.86% | -72.28% |
| Jade Biosciences, Inc. (JBIO)vs › | $819.78M | -34.83% | -64.71% | -59.77% | -96.53% |
| AdaptHealth Corp. (AHCO)vs › | $789.11M | -16.56% | 0.55% | -10.56% | -13.37% |
| Alumis Inc. (ALMS)vs › | $825.76M | -97.08% | -96.94% | -22.72% | -22.72% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $784.88M | -13.30% | 11.91% | 154.09% | 54.89% |
| Beta Bionics, Inc. (BBNX)vs › | $834.78M | -28.46% | -48.75% | -33.66% | -33.66% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $841.42M | -33.06% | -24.59% | -41.17% | -18.72% |
| Geron Corporation (GERN)vs › | $769.83M | -31.97% | -50.13% | -87.97% | -79.93% |
ROE
12.3%
ROA
10.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 12.32% |
| 2026-03-31 | 13.19% |
| 2025-12-31 | 13.73% |
| 2025-09-30 | 22.89% |
| 2024-06-30 | 19.86% |
| 2024-03-31 | 22.21% |
| 2023-12-31 | 25.14% |
| 2023-09-30 | 24.94% |
| 2023-06-30 | 27.43% |
| 2023-03-31 | 28.37% |
| 2022-12-31 | 29.12% |
| 2022-09-30 | 34.72% |
| 2022-06-30 | 38.08% |
| 2022-03-31 | 41.98% |
| 2021-12-31 | 39.68% |
| 2021-09-30 | 38.80% |
| 2021-06-30 | 38.70% |
| 2021-03-31 | 32.42% |
| 2020-12-31 | 29.54% |
| 2020-09-30 | 24.98% |
| 2020-06-30 | 24.49% |
| 2020-03-31 | 29.49% |
| 2019-12-31 | 34.73% |
| 2019-09-30 | 26.35% |
| 2019-06-30 | 48.95% |
| 2019-03-31 | 48.49% |
| 2018-12-31 | 51.71% |
| 2018-09-30 | 58.56% |
| 2018-06-30 | 56.30% |
| 2018-03-31 | 65.99% |
| 2017-12-31 | 49.54% |
